Phathom PharmaceuticalsPHAT
PHAT
About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees: 427
0
Funds holding %
of 7,428 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
37% more capital invested
Capital invested by funds: $401M [Q1] → $549M (+$148M) [Q2]
22% more call options, than puts
Call options by funds: $10M | Put options by funds: $8.26M
17% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
9.95% less ownership
Funds ownership: 91.94% [Q1] → 81.99% (-9.95%) [Q2]
17% less funds holding
Funds holding: 137 [Q1] → 114 (-23) [Q2]
53% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 36
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
47%
upside
Avg. target
$22
87%
upside
High target
$28
142%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Chase Knickerbocker | 47%upside $17 | Buy Maintained | 9 Jun 2025 |
HC Wainwright & Co. Matthew Caufield | 73%upside $20 | Buy Reiterated | 9 Jun 2025 |
Needham Joseph Stringer | 142%upside $28 | Buy Maintained | 6 Jun 2025 |
Financial journalist opinion
Based on 8 articles about PHAT published over the past 30 days
Neutral
GlobeNewsWire
21 hours ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
Positive
Zacks Investment Research
3 days ago
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
5 days ago
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom.
Neutral
Seeking Alpha
2 weeks ago
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Eric Sciorilli - Corporate Participant Robert Breedlove - VP of Finance & Principal Accounting Officer Steven L. Basta - CEO, President & Director Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Robert Stringer - Needham & Company, LLC, Research Division Jyhhaw Liu - Evercore ISI Institutional Equities, Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Matthew Coleman Caufield - H.C.
Positive
The Motley Fool
2 weeks ago
Phathom (PHAT) Q2 Revenue Jumps 441%
Phathom (PHAT) Q2 Revenue Jumps 441%
Negative
Zacks Investment Research
2 weeks ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.25 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates.
Neutral
GlobeNewsWire
4 weeks ago
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, August 7, 2025, to report its second quarter 2025 financial results and provide a business update.
Positive
Seeking Alpha
2 months ago
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insurance coverage have driven $55M+ first-year sales and 390,000+ prescriptions. Discounted cash flow analysis supports a $14/share price target (43% upside potential), with near-term catalysts in sales growth, EU partnerships, and pipeline expansion.
Neutral
GlobeNewsWire
2 months ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards.
Charts implemented using Lightweight Charts™